Neuralink Corp., the brain-computer interface startup co-founded by Elon Musk, has raised a staggering $650 million in Series E funding, marking a pivotal moment in its mission to revolutionize how the brain connects with machines. The raise, which reportedly gives the company a pre-money valuation of $9 billion, more than doubles its previous valuation and underscores growing investor confidence in neurotechnology.
The funding round attracted participation from a notable lineup of backers including Sequoia Capital, Lightspeed Venture Partners, Thrive Capital, and ARK Invest, as well as Founders Fund. Many of these investors are no strangers to Musk-led ventures and the frontier of emerging technologies.
This significant capital injection comes amid rapid progress in Neuralink’s hardware development and clinical research. Since its $280 million Series D round in 2023 (which later saw a $43 million top-up), Neuralink has advanced its flagship product — the N1 implant — from concept into early clinical trials.
Pioneering the Mind-Machine Interface
The N1 implant, about the size of a coin, is designed to allow individuals with severe motor disabilities such as quadriplegia to control external devices — including computers — directly with their thoughts. The device connects to the brain through 1,024 ultra-thin electrodes and operates on custom chips powered by a rechargeable onboard battery. It charges wirelessly and is implanted via a robotic surgical system developed in-house, known as R1.
The R1 robot uses advanced optical systems, including optical coherence tomography (OCT), to ensure precision during surgery. The company says five human subjects have already received the implants in ongoing clinical trials, with partnerships involving three U.S. universities.
Expanding the Vision Beyond Movement
In addition to enabling movement and communication for patients with paralysis, Neuralink has disclosed that it is developing two other implants focused on restoring vision and enabling speech. These devices have been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), a status that accelerates the regulatory review process for promising medical technologies.
Related story: Elon Musk’s Neuralink cleared to launch clinical trials in Canada
The fresh funds will be used to expand engineering and clinical teams, scale hardware production, and widen patient access through new or expanded trials. The company is actively hiring to meet the demands of its ambitious roadmap.
Rising Competition in Brain-Tech
Neuralink is not alone in the race to link minds with machines. Competitors like Synchron Inc., backed by Jeff Bezos’ Expeditions fund, are also developing brain-computer interface solutions, though via less invasive techniques. Synchron is currently working with Apple Inc. to allow users to control iPhones with their thoughts, and recently partnered with Nvidia Corp. to reduce latency through AI-enhanced software.
Meanwhile, Starfish Neuroscience, another entrant in the space, is preparing to launch a compact, battery-free implant by the end of the year.
Charting the Future of Human-Machine Integration
With its latest funding round, Neuralink is poised to scale its ambitions — moving from breakthrough prototypes to potential real-world applications. If successful, Musk’s brain-chip venture could redefine the boundaries of human capability, particularly for people with severe neurological conditions.
As the field of neurotechnology heats up, all eyes will be on Neuralink to see whether it can turn its futuristic promise into a practical, life-changing reality.
